HematologyNews.net

Hematology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Ibrutinib"

Bruton's tyrosine kinase ( BTK ) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, Ibrutinib ( Imbruvica ), a BTK inhibitor, ...


Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ...


The Food and Drug Administration ( FDA ) has expanded the approved use of Imbruvica ( Ibrutinib ) for chronic lymphocytic leukemia ( CLL ) patients who have received at least one previous therapy.Chro ...


Patients with chronic lymphoid leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ) who experience short response duration or adverse cytogenetics have poor outcomes. Researchers have evaluated th ...


Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in eld ...


Results from a sub-analysis of the phase 2 RESONATE-17 study has shown Ibrutinib ( Imbruvica ) was associated with robust efficacy and a positive risk-benefit profile in patients with relapsed or refr ...


A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma ( DLBCL ) are more likely to respond to the drug Ibrutinib ( Imbruvica ) than patients with ...


RESONATE-2 is a phase 3 study of first-line Ibrutinib ( Imbruvica ) versus Chlorambucil in chronic lymphocytic leukemia ( CLL ) / small lymphocytic lymphoma ( SLL ). Patients aged greater than or ...


The safety and efficacy of Ibrutinib ( Imbruvica ), a once-daily Bruton's tyrosine kinase inhibitor, in chronic lymphocytic leukemia / small lymphocytic lymphoma ( CLL/SLL ) was demonstrated in this ...


Ibrutinib ( Imbruvica ) has shown single-agent activity in relapse / refractory ( R/R ) primary central nervous system lymphoma ( PCNSL ), and the high dose Methotrexate ( HD-MTX ) has been the backbo ...


Central nervous system ( CNS ) relapse of mantle cell lymphoma ( MCL ) is a rare phenomenon for which a standard of care has not been identified. Responses to conventional treatment for CNS-MCL are ...